SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-20-008413
Filing Date
2020-04-02
Accepted
2020-04-02 08:06:19
Documents
13
Period of Report
2020-04-02
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea120369-8k_nektartherap.htm   iXBRL 8-K 28046
2 COMMUNICATION TITLED "A LETTER FROM OUR PRESIDENT AND CEO, HOWARD ROBIN (UPDATED ea120369ex99-1_nektartherap.htm EX-99.1 8242
  Complete submission text file 0001213900-20-008413.txt   214512

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE nktr-20200402.xsd EX-101.SCH 3206
4 XBRL LABEL FILE nktr-20200402_lab.xml EX-101.LAB 34581
5 XBRL PRESENTATION FILE nktr-20200402_pre.xml EX-101.PRE 22720
7 EXTRACTED XBRL INSTANCE DOCUMENT ea120369-8k_nektartherap_htm.xml XML 3497
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 20767401
SIC: 2834 Pharmaceutical Preparations